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Objective: It is thought that adult human mesenchymal stem cells do not induce
immunoreactivity even to xenografts. We wanted to study whether adult human
mesenchymal stem cells survive and engraft in experimentally induced ischemic rat
myocardium.
Methods: Bone marrow–derived adult human mesenchymal stem cells (2.5  106)
were injected into the myocardium of 4 Sprague-Dawley rats. One week after
injection, peripheral blood rat lymphocytes were added to adult human mesenchy-
mal stem cells in a mixed lymphocyte reaction. Furthermore, an infarction was
created by left anterior descending artery ligation of 8 Sprague-Dawley rats, 4 of
which were immunosuppressed with tacrolimus (0.1 mg/kg/d) and 4 RNU athymic
rats. One week after left anterior descending artery ligation, 2.5 to 3.5  106 adult
human mesenchymal stem cells were injected around the infarcted area. The adult
human mesenchymal stem cells were identified with fluorescence in situ hybridiza-
tion technique and myocardial antigens by immunohistochemistry. The immune
response was studied by hematoxylin and eosin staining and by antibodies directed
toward macrophages.
Results: Significant rat lymphocyte proliferation was observed when adult human
mesenchymal stem cells were added to peripheral blood from Sprague-Dawley rats
previously exposed to adult human mesenchymal stem cells. No reactivity was seen
in lymphocytes from untreated Sprague-Dawley rats and athymic rats. Adult human
mesenchymal stem cells could only be identified in the myocardium of athymic rats.
Further, in normal Sprague-Dawley rats, there was a significant myocardial infil-
tration of round cells, mostly macrophages, in the area of injection of adult human
mesenchymal stem cells. In RNU rats, this reaction was less intense.
Conclusion: Adult human mesenchymal stem cells did not induce xenoreactivity in
vitro in previously unexposed immunocompetent Sprague-Dawley rats. However,
although mesenchymal stem cells are transplantable across allogeneic barriers,
transplant rejection can occur in a xenogenic model. When transplanted into an
immunoincompetent host, adult human mesenchymal stem cells showed persistent
engraftment.
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Survival of implanted cells and improved heartfunction has been reported after transplanta-tion of fibroblasts,1 skeletal myoblasts,2-5 fe-tal and autologous cardiomyocytes,1,6-11 andbone marrow cells.12,13
Mesenchymal stem cells (MSC) are nonhematopoietic
pluripotent cells present in adult bone marrow that can
differentiate in vitro and in vivo to osteocytes, chondro-
cytes, adipocytes, and cardiomyocytes.14-16 Human MSC
express intermediate levels of human leukocyte antigen
(HLA) major histocompatibility complex (MHC) class I
molecules and can be induced by interferon- to express
HLA class II and Fas ligand; they do not express the
costimulatory molecules B7-1, B7-2, CD40, or CD40 li-
gand.17 They should therefore be recognized by alloreactive
T cells. However, human, baboon, and murine MSC failed
to elicit a proliferative response from allogeneic lympho-
cytes.17-21 When precultured with interferon- for full HLA
class II expression, MSC still escape recognition by allo-
reactive T cells. Unlike other nonprofessional antigen-pre-
senting cells, this failure is not reversed by provision of
CD28-mediated costimulation.17 Furthermore, MSC are im-
munosuppressive and inhibit T-cell alloreactivity induced in
mixed lymphocyte cultures (MLC) or by nonspecific mito-
gens.17,18,20-22 MSC-induced T-cell suppression appears to
include both naı¨ve and memory T cells. It is dose-dependent
and has no immunologic restriction because both autolo-
gous and third-party MSC equally reduce lymphocyte pro-
liferation.
Given the unique immunologic properties of adult hu-
man MSC (ahMSC) and their ability to survive in the host
after allogeneic transplantation, the purpose of the present
study was to investigate whether ahMSC can engraft and
survive in a xenogenic immunocompetent environment.
Methods
Experimental Animals
Fourteen Sprague-Dawley (SD) rats (B&K Universal AB, Sollen-
tuna, Sweden) weighing 400 to 450 g and 4 RNU rats (Charles
River Deutschland Inc, Sulzfeld, Germany) weighing 250 to 300 g
were used altogether in this experiment. The Animal Care Com-
mittee at the Huddinge University Hospital approved all proce-
dures. The animals received human care in compliance with the
“Guide for the Care and Use of Laboratory Animals” prepared by
the Institute of Laboratory Animal Resources, National Research
Institute, and published by the National Academy Press.23
Stem Cell Isolation Procedure
To isolate ahMSC, bone marrow aspirates of 5 to 10 mL were
taken from the sternum of patients undergoing a cardiac operation.
The Ethical Committee at Huddinge University Hospital approved
the study. MSC were isolated and cultured as previously report-
ed.21,24 Mononuclear cells recovered from the interface of Percoll-
separated bone marrow were washed and resuspended in human
MSC medium consisting of Dulbecco’s modified Eagle’s medium-
low glucose (Life Technologies, Gaithersburg, Md) supplemented
with 10% fetal bovine serum (Sigma-Aldrich Corp, St Louis, Mo),
1% antibiotic-antimycotic solution (Life Technologies), and plated
at 3  107 cells/185 cm2 in Nunclon Solo flasks (Fisher Scientific,
Pittsburgh, Pa). Cultures were maintained at 37°C in a humidified
atmosphere containing 5% CO2. When the cultures were near
confluence, the cells were detached by treatment with trypsin and
ethylenediaminetetraacetic acid (EDTA; GibcoBRL, Grand Island,
NY) and replated (passaged) at a density of 1  106 cells per
185-cm2 flask. After 3 passages, cells were harvested by treatment
with 0.05% trypsin-EDTA and washed with phosphate-buffered
saline solution (PBS).
By flow cytometry, cultured MSC were uniformly positive for
CD166, CD105, CD44, CD29, SH3, and SH4 and negative for
hematopoietic markers CD14, CD34, and CD45. On induction, the
cells differentiated to osteoblasts, adipocytes, and chondrocytes, as
previously described.21
Anesthesia and Postoperative Care
The rats were anaesthetized with an intramuscular injection of
dormicum (5 mg/kg; F. Hoffmann-La Roche Ltd, Basel, Switzer-
land) and domitor vet (0.1 mg/kg; Orion Corp, Espoo, Finland) and
were subsequently endotracheally intubated. Positive-pressure
ventilation was maintained at a rate of 120 cycles per minute with
a tidal volume of 1.5 mL with room air supplemented with oxygen
(2 L/min) using a Zoovent ventilator (Model CWC600AP; BK
Universal, Harvard, UK). The anesthesia was reversed by an
intramuscular injection of lanexat (0.1 mg/kg; F. Hoffmann-La
Roche Ltd) and antisedan vet (5 mg/kg; Orion Corp). The rats were
monitored for 2 hours postoperatively and then returned to their
cages. The RNU rats were held under isolated conditions in spe-
cially designed cages with enhanced ventilation.
Myocardial Scar Formation and ahMSC Implantation
Under general anesthesia a left lateral thoracotomy and pericar-
diotomy was performed, exposing the heart. The left anterior
descending artery (LAD) was identified and ligated with a 7-0
polypropylene suture. The thoracotomy was closed with running
sutures of vicryl and the left pleura was deaired with a 10-mL
syringe. After 1 week the rats underwent a rethoracotomy and the
infarcted area was identified. The ahMSC were suspended in 100
L PBS and subsequently injected into the myocardium surround-
ing the infarcted scar. The control rats were injected with 100 L
PBS without any ahMSC. The thoracotomy was closed in the same
manner as earlier described and the anesthesia was reversed. The
RNU rats were operated under sterile conditions in a ventilated
chamber. The SD rats were operated under clean but nonsterile
conditions.
The rats were divided into 3 groups with 4 rats in each. Three
rats in each group received ahMSC and the remaining rat func-
tioned as a control and received 100 L PBS. Group 1 was SD rats
who were not immunosuppressed, and group 2 was SD rats im-
munosuppressed with tacrolimus (0.1 mg/kg/d; Fujisawa Health-
care, Inc, Deerfield, Ill) given intramuscularly. These 2 groups
received 3.5  106 ahMSC. Group 3 was athymic RNU rats,
without the need of immunosuppression, who received 2.5  106
ahMSC.
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Detection of Transplanted Cells and Evaluation of
Differentiation Markers
One week after the intracardiac injection of ahMSC, the hearts
were removed, rinsed with PBS, and fixed in buffered formalin
solution for 24 hours. The hearts were then embedded in paraffin
and cut into 3-m thick sections by the use of a microtome
(Microm, HM 355S, Microm Laborgera¨te GmbH, Walldorf, Ger-
many). The sections were subsequently prepared for hematoxylin
and eosin staining to identify the site of injection and thereby
identify the area with the implanted cells. It was reasoned that
detection of DNA sequences specific for the human genome would
provide unequivocal genetic evidence for identification of grafted
cells. The fluorescent in situ hybridization technique (FISH) was
used, allowing the detection of specific nucleic acid sequences in
histological sections. The FISH procedure has been previously
described7 and in brief our modified version involves the following
steps. The paraffin slides were baked at 60°C for 2 hours, the
paraffin was removed, and a rehydration process was performed
using 95%, 70%, and 50% ethanol, respectively. The slides were
microwave-treated in citrate buffer (10 mmol/L, pH 6.0) for 1.5
minutes at 750 W followed by 4.5 minutes at 50 W. A mixture of
0.5 mL of pepsin (Sigma p7012) and 50 mL of HCl (150 g/mL)
was applied to each slide and incubated at 37°C for 15 to 20
minutes and in 2 sodium citrate-sodium chloride buffer (SSC)
with 0.1% igepal (Sigma-Aldrich Corp) for 10 minutes. The slides
were then incubated in 1% formaldehyde/50 mmol/L MgCl2/PBS
for 10 minutes at 20°C and in PBS for another 5 minutes, followed
by dehydration. Then 3 L FISH probe cocktail (Vysis Inc,
Downers Grove, Ill) was applied to each section. The next step
consisted of simultaneous denaturation of probe and target DNA at
74°C for 10 minutes. The slides were subsequently incubated
overnight in a humidified chamber at 39°C to allow hybridization
of probe and target DNA. After repeated washes, the remaining
probe molecules were stained with antifade containing 4,6-dia-
mino-2-phenylindole. Slides were then examined using an Olym-
pus DP10 fluorescent microscope (Olympus BX60, Olympus Op-
tical Co, Ltd, Tokyo, Japan) where the nuclei of the transplanted
cells stained red.
Slides with transplanted cells, identified with the FISH proce-
dure, were incubated with antibodies directed against cardiac-
specific antigens. The sections were rinsed in PBS and blocked by
incubating the sections in 5% rabbit serum (X0902, Dako,
Glostrup, Denmark) for 30 minutes. The slides were incubated
overnight at room temperature with mouse monoclonal antibodies
specific for desmin (clone DE-R-11, Dako), sarcomeric actin
(clone 5C5, Sigma-Aldrich Corp), myosin (clone NOQ7.5.4D,
Sigma-Aldrich Corp), tropomyosin (T9283 clone CH1, Sigma-
Aldrich Corp), and connexin 43 (clone CXN-6, Sigma-Aldrich
Corp). The sections were incubated with fluorescence-labeled rab-
bit anti-mouse antibodies in the blocking solution at the dilution
1:10 (fluorescein isothiocyanate [FITC]-labeled, F0313, Dako) and
visualized by fluorescence microscope.
Immunohistochemical Characterization of Graft-
Infiltrating Cells
Cellular infiltration was detected by hematoxylin and eosin stain-
ing. Paraffin sections with lots of round cells were further stained
with antibodies against macrophages. The paraffin was removed in
xylene and rehydrated in ethanol (95%, 70%, 50%) and in distilled
water for 2 minutes each. The slides were then treated in citrate
buffer (10 mmol/L, pH 6) in the microwave at 750 W for 1 minute
and then for 5 minutes at 50 W. The sections were incubated in 2
 SSC with 0.1% igepal for 10 minutes at 37°C then were
incubated overnight at 20°C with the primary antibody (mouse
anti-rat ED1MCA341R, Serotec, Oxford, England), diluted 1:40 in
permeabilization buffer (Dako). After washing in 1  PBS, the
slides were incubated with the secondary fluorescence-labeled
rabbit anti-mouse antibody, diluted 1:20 in permeabilization buffer
(FITC-labeled, F0313, Dako) for 2 hours, and then visualized in
the fluorescence microscope.
Mixed Rat Lymphocyte Human MSC Cultures
To evaluate whether the ahMSC elicit an immune response or not,
mixed lymphocyte reaction (MLR) test was performed on periph-
eral blood (PBL) from SD rats injected with 2.5  106 ahMSC. A
separate experiment was performed with 5 SD rats. Blood from 3
of the rats who received ahMSC were pooled, and blood samples
from the other 2 rats (1 control) were tested separately. We also
collected peripheral blood from 1 rat in each of the 3 groups
described above, including 1 control rat who received PBS. This
was done at the same time as these rats were killed and the hearts
taken out for further analysis. Lymphocytes from each sample
were separated on a Ficoll-Isopaque density gradient (Lym-
phoprep, Nyco, Norway). The cells were washed twice and sus-
pended in Roswell Park Memorial Institute (medium) with fetal
calf serum 5%, mercaptoethanol 105 mol/L, and antibiotics.
MLR was performed as previously described.21 In short, 1  105
responder cells were cocultured with 1  105 irradiated stimulator
cells, which were inactivated by 20-Gy irradiation. To each cul-
ture, 0, 1  103 or 1  105 ahMSC were added. 3H-thymidine
(Radiochemical Center, Amersham, UK) with a specific activity of
5 Ci/mmol/L was added to each culture 24 hours prior to harvest.
The cells were harvested automatically on a glass fiber filter using
a Tomtec harvesting machine (Tomtec, Orange, Conn) on day 6.
Tritiated thymidine incorporation is expressed as counts per
minute (cpm).
Results
Myocardial Infarction Model
One SD rat died 2 days after the intramyocardial cell injec-
tion. The other rats survived the whole process without any
apparent signs of discomfort.
Histological Analysis
The LAD ligation led to a transmural infarction in the
anterior wall of all examined rats. Fibrous scar tissue had
developed in the infarction area, visualized in hematoxylin
and eosin staining (Figure 1). The implanted ahMSC were
detected in large amounts in the myocardium of RNU rats
(Figure 2), but they could not be found in SD rats. The
implanted cells stained negative for all the monoclonal
antibodies specific for cardiomyocyte antigens and con-
nexin 43. In histological sections the implanted cells seem
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to be randomly dispersed in a disorganized way, without
any sign of alignment, around the infarcted area.
MLR and Cellular Immune Response
In the first set of experiments, PBL from SD rats collected
7 days after cardiac injection of ahMSC were mixed with
1% or 10% ahMSC. 3H thymidine uptake was measured and
compared with that of the control rat (with no previous
exposure to ahMSC). In the first set of experiments, ahMSC
were injected into the myocardium of SD rats without LAD
ligation. As shown in Figure 3, significant lymphocyte
proliferation (P  .01) was observed when ahMSC were
cocultured with lymphocytes from SD rats previously ex-
posed to ahMSC. No immune response was detected in
animals not previously exposed to ahMSC.
To evaluate if ahMSC induced a sensitization reaction in
SD rats immunosuppressed with therapeutic levels of ta-
crolimus and in RNU rats, PBL from these rats in the
infarction model were analyzed in MLR. Lymphocyte pro-
liferation was not significantly increased in PBL from SD
rats with immunosuppression when exposed to ahMSC. The
ahMSC did not elicit any proliferation in lymphocytes from
RNU rats (Figure 4). However, significant proliferation was
observed in animals without immunosuppression post-
ahMSC injection, indicating a sensitization reaction.
In normal SD rats, without immunosuppression, there
was an intense cellular immune response in the area of
injection of stem cells, mediated primarily by macrophages
(Figures 5 and 6). This cellular immune response increased
significantly from day 2 to day 7. We could not demonstrate
almost any macrophage infiltration in SD rats immunosup-
pressed with tacrolimus. The macrophage-mediated im-
mune response was significantly less prominent in the im-
munoincompetent RNU rats (Figure 6).
Discussion
In the present study, we investigated the fate of adult human
bone marrow–derived MSC after injection into immuno-
competent SD rats, with or without immunosuppression.
ahMSC were also injected into the heart of athymic RNU
rats that have an impaired response against xenogenic im-
plants. We found that although ahMSC were present in all
hearts 2 days postinjection, SD rats without immunosup-
pression, unlike the other animals, showed infiltration of
inflammatory cells. One week posttransplant, ahMSC could
no longer be detected in SD rats without tacrolimus. Immu-
nofluorescence showed massive macrophage infiltration. In
MLC, significant lymphocyte proliferation was observed
when ahMSC were added to SD rats previously exposed to
ahMSC, indicating an immune reaction against transplanted
cells.
Numerous reports have indicated that MSC possess
unique immunologic properties. Transplantation of alloge-
neic mismatched MSC to adult animals has shown engraft-
ment in murine and baboon experimental models.25,26 In
vitro studies of human MSC show that the cells fail to elicit
proliferation of allogeneic lymphocytes even in the presence
of CD28-mediated costimulation.17-21 The immunologic
and multipotential characteristics of the cells used in the
present study have previously been described in detail.21
The cells comprise a phenotypically homogenous popula-
tion without contamination of hematopoietic cells. In cocul-
ture experiments, the cells do not elicit alloreactivity of
autologous or allogeneic human lymphocytes. In MLC, they
suppress the proliferation of T cells stimulated by cellular or
Figure 1. Representative photomicrograph of a transmural scar
lesion, 1 week after LAD ligation in an SD rat. (Hematoxylin and
eosin, 10.)
Figure 2. Identification of transplanted ahMSC 1 week after
transplantation in an RNU rat. In situ hybridization of the chro-
mosomes in the transplanted ahMSC stains red.
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humoral antigens in a dose-dependent manner. Further char-
acterization of the cells after differentiation in vitro has
shown that MSC differentiated into adipose, bone, and
cartilage express HLA class I but no longer express class II
after interferon- exposure.27 The differentiated cells are
not inherently immunogenic. Instead, differentiation, partic-
ularly along the osteogenic lineage, enhances the suppres-
sive effect in third-party MLC. Moreover, the immuno-
modulatory effect of undifferentiated and differentiated
MSC is further enhanced after treatment with interferon-.
In accordance with our previous results on allogeneic
human lymphocytes, no proliferation was detected when
Figure 3. Responsiveness of SD rat lymphocytes to ahMSC 7 days after injection of ahMSC (B, pooled peripheral
blood from 3 syngenic rats; C, 1 individual rat) and with no previous exposure to ahMSC (A), as assayed by MLR.
Experiments were performed in triplicate with a significance of P < .01. Mean  SD.
Figure 4. ahMSC elicit a significant proliferative response when cultured with PBL from SD rats but not from RNU
rats previously exposed to ahMSC (P < .01). Rat PBL (1  105) were cultured with 1  105 irradiated autologous
lymphocytes in the absence (Bg, Background) or presence (MSC) of 1 104 ahMSC. Each bar depicts 1 experiment
performed in triplicate. K, control animals; SD, PBL from SD rats 7 days post– cardiac injection of ahMSC; RNU, PBL
from an athymic RNU rat 7 days post– cardiac injection of ahMSC. Mean  SD.
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ahMSC were cocultured with SD rat lymphocytes. How-
ever, in immunocompetent animals that had received an
injection of ahMSC, significant proliferation was observed
in coculture experiments. This indicates that an immune
reaction had occurred against the transplanted cells. The
finding differs from results obtained after allogeneic trans-
plantation of ahMSC in humans. No alloreactive prolifera-
tion can be detected when patient lymphocytes are reex-
posed to the transplanted allogeneic ahMSC in cocultures
(Le Blanc and colleagues, unpublished observation). As
expected, no T-cell proliferation was induced in rechal-
lenged RNU rats that lack the ability to mount an adaptive
immune response.
Histological examination of sectioned hearts further sup-
ported a rejection of transplanted ahMSC in SD rats. Round
cell infiltration was noted 2 days posttransplant and was
massive after 1 week. Transplanted ahMSC could be found
Figure 5. Round cell infiltration in the myocardium of normal SD
rats: (A) 2 days and (B) 1 week after injection of stem cells and
(C) in immunosuppressed SD rats. (Hematoxylin and eosin, 20.)
Figure 6. Immunofluorescence showing infiltration of macro-
phages (green spots) at the site of injection of stem cells in (A)
normal SD rats and (B) RNU rats.
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on day 2 but not after 1 week. Infiltrating cells stained
positive for macrophage markers. In SD rats treated with
tacrolimus and in RNU rats, the macrophage infiltration was
less prominent.
Mixed lymphocyte cultures are in vitro measures of the
CD4 and CD8 T-cell proliferation in the lymph node initi-
ated by antigen-presenting cells. Following xenotransplan-
tation, in vivo immune responses include both acquired
immunity and innate immunity, in which natural antibody,
complement, natural killer cells, and macrophages all play
independent roles.28 In accordance with this, in our system,
we observed round cell infiltration that stained positive for
macrophages at the time that the grafted cells disappeared.
The paraffin-embedded material did not allow staining with
antibodies specific for lymphocyte subsets, immunoglobulin
deposition, or complement to study the mechanism whereby
rejection occurred. However, the combination of these find-
ings, the persistence of transplanted cells in athymic rats and
an immunologic response when lymphocytes from trans-
planted immunocompetent animals were reexposed to
ahMSC, strongly indicates rejection rather than unspecific
inflammation. The mechanism behind the rejection will be
the subject of future studies.
Our findings contrast with the results of Saito and col-
leagues,29 who reported on immunologic tolerance to mouse
MSC allowing engraftment in the injured myocardium of
immunocompetent rats, suggesting that the cells impart
tolerogenic properties in that xenogenic environment. This
discrepancy could be explained by the fact that the trans-
planted cells were derived from different species. Although
both human and murine MSC are immunosuppressive, ma-
jor differences exist between MSC from the 2 species.
Murine MSC, unlike their human equivalent, lack MHC
class II expression.22 Furthermore, T-cell inhibition by mu-
rine MSC requires cell contact whereas the suppressive
effect by human MSC appears to be mediated by a soluble
factor (Le Blanc and colleagues, unpublished observa-
tion).17,20 After intrauterine transplantation of ahMSC into
sheep, the cells showed long-term engraftment and differ-
entiated along multiple mesenchymal lineages.14 It is of
particular interest that engraftment occurred even when the
transplant was performed after the fetuses became immu-
nocompetent. However, species-specific differences in im-
munologic tolerance may exist between sheep and rodents
that could account for the discrepant results. Furthermore,
although the ahMSC were transplanted into the fetal sheep
after the expected development of immunologic compe-
tence, transplanted ahMSC were detected in the thymic
stroma. It therefore could be argued that the sustained
engraftment of xenogenic MSC in the fetuses not only
results from active suppression of host T cells but also from
the development of central deletional tolerance.
Toma and colleagues13 demonstrated the potential of
ahMSC to undergo cardiomyogenic differentiation in the
heart of an immunoincompetent murine host, although en-
graftment was limited after direct injection. This agrees with
our findings of large amounts of ahMSC in the immunoin-
competent RNU rats. The ahMSC that survived in the RNU
rats 1 week after implantation had not migrated within the
myocardium and had not differentiated toward cardiomyo-
cytes. Moreover, they did not communicate with each other
through gap junctions. Wang and coworkers30 demonstrated
the presence of connexin 43 after intracoronary delivery of
MSC; however, these animals were sacrificed after 4 weeks.
Furthermore, Tomita and colleagues31 found autologous
porcine bone marrow cells 4 weeks after transplantation
within the infarct region, which seemed to have sarcomeres
and Z-bands as well as expressing troponin I. This indicates
that not only do ahMSC survive after transplantation but
also that they seem to differentiate toward cells that appear
to be similar to cardiomyocytes. Therefore, our observation
period of 1 week is likely to be too short for the ahMSC to
differentiate toward cells with a myogenic phenotype.
In conclusion, we found that ahMSC did not induce
xenoreactivity in vitro in previously unexposed immuno-
competent SD rats. However, although MSC are transplant-
able across allogeneic barriers, transplant rejection can oc-
cur in a xenogenic model. When transplanted into an
immunoincompetent host, ahMSC showed persistent en-
graftment.
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